openPR Logo
Press release

MicroRNA Market:Impact of Existing and Emerging Market 2020

10-26-2016 09:56 AM CET | Health & Medicine

Press release from: Persistence Market Research Pvt. Ltd

MicroRNA, also known as miRNA, is a class of non-coding ribonucleic acid (RNA) which plays a vital role in the regulation of gene expression. It founds in animals, plants and some viruses and also involved in RNA silencing. RNA silencing is a term that refers to a family of gene silencing in which expression of one or more gene is suppressed by small RNAs.

Request to view Sample Report @ http://www.persistencemarketresearch.com/samples/3464

MicroRNA regulates several biological processes. It includes apoptosis, cell cycle control and several developmental and physiological processes such as stem cell differentiation, hypoxia, cardiac and skeletal muscle development, hematopoiesis, neurogenesis, cholesterol metabolism, insulin secretion, aging and viral replication.

The global microRNA market is categorized based on various diagnostic technologies, therapeutics and by research tools and reagents. The research tools and reagent is the largest segment of global microRNA market. However, microRNA diagnostics is the fastest growing segment of global microRNA market.

In terms of geographic, North America and Europe dominates the global microRNA market. This is due to improved life science research infrastructures in these regions. The U.S. represents the largest market for microRNA followed by Canada in North America. Germany, France, Italy, Spain and the U.K. holds major share of microRNA market in Europe. However, Asia is expected to show high growth rates in the next five years in global microRNA market due to increased investment by major companies in the region. In addition, less stringent regulations has also fueled the growth of microRNA market in Asia. China and India are expected to be the fastest growing microRNA markets in Asia.

In recent time, increasing prevalence of diseases, such as cancer and cardiovascular diseases, and innovative applications of the technology are some of the major drivers of the global microRNA market. For instance, according to the International Agency for Research on Cancer (IARC), a specialized agency of the WHO, about 12.7 million new cancer cases were reported in 2008 and the number reached 14.1 million in 2012. MicroRNAs are used as a biomarker for cancer diagnosis and treatment. In addition, increased research on microRNA based diagnostic tests and therapeutics has also fueled the growth of global microRNA market. This increased microRNA research continues to drive the advances of techniques for microRNA expression profiling and innovative technologies that are sensitive and specific for every biospecimens.

However, high investment cost and stringent regulations are some of the major restraints for global microRNA market. Moreover, methods used in detection of microRNA are costly and time-consuming. Equipments used in detection of microRNAs costs more than USD 1, 00,000. Thus, high investment costs hamper the growth of global microRNA market. In addition, lack of skilled professionals also obstructs the growth of global microRNA market. Increasing mergers and collaborations between biotech companies and government research organizations is key trend for the global microRNA market.

Request to view Table of content @ http://www.persistencemarketresearch.com/toc/3464

Some of the major companies operating in the global microRNA market are Affymetrix Inc., Alnylam Pharmaceuticals Inc., Santaris Pharma A/S, Exiqon A/S, AstraZeneca Pharmaceuticals LP, Biogen Idec Inc., Eli Lilly and Co., Pfizer Inc., CBC Comprehensive Biomarker Center GmbH, F. Hoffman-La Roche, GlaxoSmithKline, Merck & Co. Inc., Novartis AG and Sigma-Aldrich.

About Us

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA - Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release MicroRNA Market:Impact of Existing and Emerging Market 2020 here

News-ID: 376527 • Views:

More Releases from Persistence Market Research Pvt. Ltd

Innovative Rehabilitation Technologies Drive Growth in Stroke Rehabilitation Market to Hit Surpass US$ 679.6 Million by 2032
Innovative Rehabilitation Technologies Drive Growth in Stroke Rehabilitation Mar …
Stroke Rehabilitation Market Size The global stroke rehabilitation market size was valued at US$ 266.4 million in 2021 and is expected to grow at a CAGR of 9% from 2022 to 2032. Revenue generated from the sales of stroke rehabilitation solutions will surge to US$ 679.6 Million by the end of 2032. The growth of the market is being driven by the increasing incidence of strokes, the growing demand for innovative rehabilitation
Launch of New Laser-Based Devices by Key Players Fueling Growth of Global Aesthetic Lasers Market
Launch of New Laser-Based Devices by Key Players Fueling Growth of Global Aesthe …
Market Study on Aesthetic Lasers The aesthetic lasers market reached US$2.8 billion in global revenue in 2021, and it will continue to expand quickly, with a value CAGR of 6.4%, to reach US$5.5 billion by the end of 2032. The growth of the market is being driven by the increasing demand for minimally invasive cosmetic procedures, rising disposable income, technological advancements, and growing medical tourism. Stay Ahead with Market Intelligence Get Free
Predictive Insights for Precision Medicine: The Global Biosimulation Market is Set to Hit USD 10 billion by 2030
Predictive Insights for Precision Medicine: The Global Biosimulation Market is S …
Biosimulation Market Research The Global Biosimulation Market Size was valued at USD 2.9 billion in 2022 and is expected to reach USD 10.0 billion by 2030, registering a CAGR of 16.9% during the forecast period. The growth of the biosimulation market is being driven by the increasing use of biosimulation in a variety of applications, such as drug discovery, clinical trials, and toxicity prediction.  Market Overview The biosimulation market has experienced rapid growth
Wheelchair and Components Market: Growing Demand for Lightweight and Smart Wheelchairs to Boost Growth
Wheelchair and Components Market: Growing Demand for Lightweight and Smart Wheel …
Wheelchair and Components Market The global wheelchair and components market is projected to reach USD 17.9 billion by 2033, at a CAGR of 3.7% from 2022-2033. The growth of the market is driven by the increasing prevalence of disabilities, the rising geriatric population, and technological advancements in wheelchair design and manufacturing. Click Here to Get Free Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/12961 The global wheelchair and components market has witnessed significant growth in

All 5 Releases


More Releases for RNA

Global RNA Analysis/Transcriptomics Market Report
The Global RNA Analysis / Transcriptomics Market is projected to expand at a CAGR of 12.5% during the forecast period, to hit USD 8.1 Billion by 2026, according to a recent market report compiled by Global Market Estimates. Due to the rising need for personalized medicines, the demand for RNA Analysis / Transcriptomics is expected to raise the market demand. Browse 156 Market Data Tables and 112 Figures spread through 175
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te …
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and may
Senior experts from Exicure, Roche, GSK, BioNTech RNA Pharmaceuticals & MiNA The …
With less than 4 weeks until SMi’s 10th annual RNA Therapeutics event (http://www.therapeutics-rna.com/openpr) opens its doors in London, UK next month, registration will soon be closing and delegate places are becoming increasingly limited. Over the course of 2 focused days, attendees will be able to have an exclusive look into key developments in oligonucleotide therapeutics, mRNA technology, delivery mechanisms, and much more, led by industry leaders, scientific pioneers, and academics exploring
RNA Therapy Improves Vision in Child Blindness, hear more about recent developme …
SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year. Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved
New Confirmed Delegates & Speakers for RNA Therapeutics
SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018! Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led
Introducing the 9th Annual RNA Therapeutics 2018
As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion. One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and